Cathie Wood’s ARK Invest more than doubled its Rocket Lab (NASDAQ: RKLB) position in Q3, yet the stock sits 59% below the high it reached just months earlier.

The core problem is Neutron, the medium-lift rocket that management has explicitly tied to the company’s first quarter of positive adjusted EBITDA.

Rocket Lab pushed Neutron’s debut into 2027 on Oct. 14, after inspections uncovered voids in a first-stage tank dome, marking the fourth schedule slip since mid-2025.

On its Nov. 9 earnings call, the company still offered no firm launch date, saying only that the tank must complete a qualification process expected to finish sometime in the first quarter.

Until that milestone arrives, no launch date can be set, and without a launch date, the profitability timeline remains open-ended.

ARK held 3.56 million Rocket Lab shares valued at $248 million as of Sept. 30, a position that had grown 118% from the prior quarter and represented the firm’s 24th-largest holding at 1.4% of its 13F portfolio.

Wood’s larger aerospace conviction, however, sits elsewhere: SpaceX (SPCX) occupied ARK’s No. 2 slot at 5.9% of its disclosed holdings, and five other funds also added the private launch giant during the quarter.

Seth Klarman’s Baupost Group was among a separate cohort that turned to Honeywell Aerospace (HONA), which trades at roughly 20x forward earnings and has actually gained 6% since the Sept. 30 filing date.

Honeywell Aerospace’s analyst price target has retreated sharply, falling from $300 in late June to $193, after the stock dropped 11% in the wake of a third-quarter earnings beat complicated by persistent supply constraints.

SpaceX presents a different kind of risk: analysts have lifted their 2027 revenue estimates by 146% since June and set an average price target of $256, implying 84% upside, but the company has guided for $35 billion to $40 billion in capital expenditure for the fourth quarter alone.

For Rocket Lab, the valuation math is increasingly strained, with the stock trading on revenue multiples well above its own historical norms.

The forward price-to-sales ratio stood at 36x at the end of September, compared with a quarterly average of 23x since 2021, and the stock remains elevated relative to that benchmark even after the recent slide.

Analysts tracking the company have steadily lowered their expectations, with the consensus 2027 earnings estimate collapsing to just 3 cents per share from 16 cents a year ago, while the average price target has dropped from a peak of $117 in mid-July to around $93.

Piper Sandler delivered the most aggressive cut, slashing its target to $58 from $83, the lowest figure currently on Wall Street.

Shareholders are also absorbing the financial burden of Neutron’s construction directly: Rocket Lab has raised roughly $4.6 billion through stock sales since March 2025 to fund both the rocket program and an approximately $8 billion Iridium contract.

The Q3 share count came in at 652 million, above the 641 million the company had guided to, a sign that dilution pressure is running ahead of schedule.

Rocket Lab’s underlying launch business does offer a genuine foundation, with Electron achieving a 40.8% launch gross margin in 2025 and the company’s backlog reaching $3.57 billion after the third quarter.

The complication is that only about one-third of that backlog is expected to convert into revenue over the next 12 months, limiting near-term cash generation.

The next opportunity for clarity arrives with Rocket Lab’s fourth-quarter earnings report early in the year, followed by ARK’s mid-February 13F filing, which will reveal whether Wood continued to accumulate shares through the downturn.